Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.42 USD
Change Today -0.10 / -2.84%
Volume 166.8K
As of 5:20 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

vericel corp (VCEL) Snapshot

Open
$3.55
Previous Close
$3.52
Day High
$3.55
Day Low
$3.24
52 Week High
06/2/14 - $5.39
52 Week Low
09/23/14 - $2.55
Market Cap
81.3M
Average Volume 10 Days
56.7K
EPS TTM
$-2.98
Shares Outstanding
23.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERICEL CORP (VCEL)

Related News

No related news articles were found.

vericel corp (VCEL) Related Businessweek News

No Related Businessweek News Found

vericel corp (VCEL) Details

Vericel Corporation, a commercial-stage biopharmaceutical company, focuses on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets two autologous cell therapy products in the United States, including Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee; and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area. The company is also developing MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee; and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company, formerly known as Aastrom Biosciences, Inc., was founded in 1989 and is headquartered in Cambridge, Massachusetts.

190 Employees
Last Reported Date: 03/25/15
Founded in 1989

vericel corp (VCEL) Top Compensated Officers

Chief Executive Officer, President, Treasurer...
Total Annual Compensation: $519.6K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $204.2K
Chief Operating Officer
Total Annual Compensation: $337.7K
Compensation as of Fiscal Year 2014.

vericel corp (VCEL) Key Developments

Vericel Announces Positive Results from Phase III MACI Implant Study

Vericel Corporation has announced positive results from the three-year extension of the Phase III SUMMIT study with matrix-applied characterized autologous cultured chondrocytes, or MACI implant. In a poster presentation entitled 'SUMMIT Trial: Matrix-induced Autologous Chondrocyte Implant versus Microfracture at 3 Years,' Professor Mats Brittberg, Cartilage Research Unit, University of Gothenburg, Sweden, and colleagues reported that patients followed for three years following treatment with MACI had consistent results as those reported previously in the two-year SUMMIT trial. In the open-label, multi-center Phase III SUMMIT study, 144 patients with symptomatic articular cartilage defects in the knee were randomized to receive treatment with MACI implant or microfracture bone marrow stimulation (MFX) and followed for two years. The study found that treatment with MACI was clinically and statistically significantly better than MFX, with similar structural repair tissue and safety. The SUMMIT study concluded that 'MACI offers a more efficacious alternative than MFX with a similar safety profile for the treatment of symptomatic articular cartilage defects of the knee.' In the SUMMIT Extension trial, 128 patients (men and women aged 18 to 55) from the original SUMMIT study continue to be followed. The co-primary endpoints of the extension study are change in knee injury and osteoarthritis outcome (KOOS) pain and function scores at year 3, the same primary endpoint from the two-year SUMMIT trial. Patients treated with MACI versus MFX continue to show a statistically significant improvement from baseline in the co-primary endpoint of KOOS pain and function at year 3 (p = 0.046) with higher responder rates in the MACI group (81.5%) than in the MFX group (66.7%). Patients treated with MACI versus MFX also showed significant improvement in knee-related quality of life and other measures. The authors concluded that "the co-primary endpoints of pain and function showed significant improvement with MACI, which was statistically significantly better than with MFX.

Nelson M. Sims to Retire from the Board of Directors of Vericel Corporation

Nelson M. Sims, a director since 2006, has informed the Board of Directors of Vericel Corporation that he intends to retire from the Board of Directors upon the conclusion of his current term at the 2015 Annual Meeting of Shareholders and, therefore, will not stand for re-election.

Vericel Corporation Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 04:20 PM

Vericel Corporation Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 04:20 PM. Venue: Westin Grand Central Hotel, New York, New York, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VCEL:US $3.42 USD -0.10

VCEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $1.23 USD -0.06
Cesca Therapeutics Inc $0.89 USD -0.018
Cytori Therapeutics Inc $0.92 USD -0.07
NeoStem Inc $2.91 USD 0.00
TiGenix NV €0.70 EUR +0.002
View Industry Companies
 

Industry Analysis

VCEL

Industry Average

Valuation VCEL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERICEL CORP, please visit www.aastrom.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.